Pharma Focus Asia

Oxford Biomedica Solutions signs agreement with new partner for AAV platform

Thursday, September 15, 2022

Oxford Biomedica plc, a leading gene and cell therapy group, today announces that its subsidiary Oxford Biomedica Solutions LLC, a high-performing full-scope scope AAV manufacturing and innovation business, has signed an agreement with a new undisclosed, U.S. based, private biotechnology company. The agreement grants the partner access to Oxford Biomedica Solutions’ process and manufacturing platform, and “The Full Solution” service offering, with end-to-end capabilities for their pre-clinical gene therapy programmes.

Under the terms of the agreement, Oxford Biomedica Solutions will receive payments relating to the full scope of process development, from construct design through to toxicology manufacturing for the partner’s programmes.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, commented:
“We are delighted to announce this new AAV partnership, and look forward to offering Oxford Biomedica Solutions’ full-scope platform to our new partner and supporting them with their construct design and product development needs. This agreement marks a very important step towards achieving our strategic objective of becoming a global viral vector leader across all key vector types, delivering life changing therapies to patients.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024